Article
Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease.
Clinical pharmacology and therapeutics - 1 Dec 2017
Plantinga T S, Arts P, Knarren G H, Mulder A H, Wakelkamp I M, Hermus A R, Joosten L A, Netea M G, Bisschop P H, de Herder W W, Beijers H J, de Bruin I J, Gilissen C, Veltman J A, Hoischen A, Smit J W, Netea-Maier R T
Abstract excerpt
Agranulocytosis is a rare and serious adverse effect of antithyroid drugs, with unknown etiology. The present study aimed to uncover genetic susceptibility and underlying mechanisms of antithyroid drug-induced agranulocytosis (ATDAC). We studied two independent families with familial Graves' disease, of which several members developed ATDAC. In addition, six sporadic ATDAC patients with Graves' disease were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.